PainReform Ltd. announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 USD | -3.70% | -4.99% | -71.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-71.64% | 1.93M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- PRFX Stock
- News PainReform Ltd.
- PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy